|
17 Mar 2021 |
T-Cure Bioscience Enters Into Agreement With Rutgers to Conduct Clinical Research of Novel T Cell Receptor Therapy for Treatment of Variety of Cancers
|
|
17 Mar 2021 |
MaaT Pharma Announces Positive Topline Results from Phase 2 HERACLES Clinical Trial with Lead Microbiome Ecosystem Therapy MaaT013 in Patients with Acute Graft-versus-Host Disease
|
|
11 Mar 2021 |
Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium
|
|
10 Mar 2021 |
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 for the Treatment of Fabry Disease
|
|
09 Mar 2021 |
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX053, an mRNA for the Treatment of Glycogen Storage Disease Type III
|
|
09 Mar 2021 |
Seres Therapeutics Announces Discontinuation of Enrollment in SER-401 Study in Metastatic Melanoma
|
|
07 Mar 2021 |
BioEclipse Therapeutics Announces First Patient Dosed in Phase 1 Dose-Escalation Clinical Trial of CRX100 in Refractory Solid Tumors
|
|
06 Mar 2021 |
U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy
|
|
05 Mar 2021 |
DNAtrix Announces First Patient Dosed in Clinical Study of DNX-2440, an OX40 Ligand Expressing Immunotherapy, in Colorectal Cancer and Other Cancers with Liver Metastasis
|
|
04 Mar 2021 |
Dicerna Announces Roche’s Initiation of GalXC™ RNAi Candidate RG6346 in Phase 2 Combination Trial for Treatment of Chronic Hepatitis B Virus Infection
|
|
04 Mar 2021 |
Novadip Biosciences receives IND approval from the FDA for regenerative bone product NVD-003
|
|
03 Mar 2021 |
Century Therapeutics Completes $160 Million Series C Financing to Accelerate Development of iPSC-derived Cell Therapy Pipeline
|
|
02 Mar 2021 |
INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18
|
|
02 Mar 2021 |
PYC's Lead Investigational Drug, VP-001, Demonstrates Another Key Functional Improvement in Patient-Derived Models - A First for Any RP11 Treatment To-Date
|
|
02 Mar 2021 |
BiomX Announces Dosing of First Subject in Phase 2 Study of BX001 for Acne-Prone Skin
|
|
01 Mar 2021 |
VBL Therapeutics Announces Patient Dosing Initiated in Randomized, Controlled and Blinded Trial of VB-111 in Patients with Recurrent Glioblastoma Multiforme
|
|
01 Mar 2021 |
Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia
|
|
01 Mar 2021 |
LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich's Ataxia Gene Therapy Program (LX2006)
|
|
01 Mar 2021 |
BioInvent and Transgene has enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors
|
|
26 Feb 2021 |
XNK Therapeutics partners with Karolinska Institutet on Phase II study in patients with multiple myeloma with support from Sanofi
|
|
26 Feb 2021 |
Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45
|
|
25 Feb 2021 |
Jaguar Gene Therapy Launches with Mission to Accelerate Breakthroughs in Gene Therapy for Patients Suffering from Severe Genetic Diseases
|
|
25 Feb 2021 |
Orna Therapeutics Launches with over $100M Raised to Develop a New Class of Fully Engineered Circular RNA Therapies
|
|
24 Feb 2021 |
Decibel Therapeutics Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations
|
|
23 Feb 2021 |
MatriSys Announces Positive Results From a Phase I Study of MSB-0221 for the Topical Treatment of Atopic Dermatitis
|
